Antibodies purified from sera of HIV-1-infected patients by affinity on the heptad repeat region 1/heptad repeat region 2 complex of gp41 neutralize HIV-1 primary isolates

AIDS

Volumn 22, Issue 16, 2008, Pages 2075-2085

  Vincent, Nadine ^a   Kone, Amadou ^a   Chanut, Blandine ^a   Lucht, Frédéric ^a   Genin, Christian ^a   Malvoisin, Etienne ^a,b  

^a UNIVERSITÉ JEAN MONNET   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Antibodies; Gp41; Heptad repeat region 1 heptad repeat region 2 complex; Neutralization

Indexed keywords

C34 PEPTIDE; ENVELOPE PROTEIN; GLYCOPROTEIN GP 41; HYBRID PROTEIN; IMMUNOGLOBULIN G; MALTOSE BINDING PROTEIN; MALTOSE BINDING PROTEIN 44; MONOCLONAL ANTIBODY; N36 PEPTIDE; NEUTRALIZING ANTIBODY; PEPTIDE DERIVATIVE; RESIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; ARTICLE; BLOOD SAMPLING; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN PURIFICATION; TANDEM REPEAT; VIRUS ISOLATION;

ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; LEUCINE ZIPPERS; VIRAL ENVELOPE PROTEINS;

EID: 55249084699     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283101260     Document Type: Article

References (36)

1. Wild C, Oas T, MacDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Nat Acad Sci USA 1992; 89:10537-10541.
2. Jiang S, Lin K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365:113.
3. Eckert DM, Kim PS. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci USA 2001; 98:11187-11192.
4. Bewley CA, Louis JM, Chirlando R, Clore GM. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol Chem 2002; 277:14238-14245.
5. Liu S, Lu H, Niu J, Xu Y, Wu S, Jiang S. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005; 280:11259-11273.
6. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4:1302-1307.
7. Lalezari JP, Eron JJ, Carlson M, Cohen C, DeJesus E, Arduino RC, et al. A phase II clinical study of the long term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17:691-698.
8. Xu J-Y, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S. Epitope mapping of two immunodoinmant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol 1991; 65:4832-4838.
9. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retrovir 1994; 10:359-369.
10. Chen C-H, Matthews TJ, McDanal CB, Bolognesi DP, Greenberg ML. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol 1995; 69:3771-3777.
11. Myers R, Meiller T, Falkler W Jr, Patel J, Joseph J. A human monoclonal antibody to a cryptic gp41 epitope on HIV-1 infected cells. In: Abstract of the 93rd General Meeting of the American Society for Microbiology. Washington, D.C.: American Society for Microbiology, 1993. [Abstract T-70], p. 444.
12. Taniguchi Y, Zolla-Pazner S, Xu Y, Zhang X, Takeda S, Hattori T. Human monoclonal antibody 98-6 reacts with the fusogenic form of gp41. Virology 2000; 273:333-340.
13. Chen C-H, Greenberg ML, Bolognesi DP, Matthews TJ. Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41. AIDS Res Hum Retrovir 2000; 16:2037-2041.
14. Corny MK, Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol 2000; 74:6186-6192.
15. Kilgore NR, Salzwedel K, Reddick M, Allaway GP, Wild CT. Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 2003; 77:7669-7672.
16. de Rosny E, Vassell R, Wingfield PT, Wild CT, Weiss CD. Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol 2001; 75:8859-8863.
17. Golding H, Zaitseva M, de Rosny E, King LR, Manischewitz J, Sidorov I, et al. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol 2002; 76:6780-6790.
18. Earl PL, Broder CC, Doms RW, Moss B. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 1997; 71:2674-2684.
19. Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998; 72:10213-10217.
20. Opalka D, Pessi A, Bianchi E, Ciliberto G, Schleif W, McElhaugh M, et al. Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods 2004; 287:49-65.
21. Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, et al. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Intern Immunol 1997; 9:1281-1290.
22. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
23. Cavacini LA, Duval M, Robinson J, Posner MR. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 2002; 16:2409-2417.
24. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Ollmann-Saphire E, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75:10892-10905.
25. Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J Virol 1996; 70:1651-1667.
26. Vincent N, Malvoisin E, Pozzetto B, Lucht F, Genin C. Detection of IgA inhibiting the interaction between gp120 and soluble CD4 receptor in serum and saliva of HIV-1-infected patients. AIDS 2004; 18:37-43.
27. Usami O, Xiao P, Ling H, Hattori T. Competitive study of monoclonal antibodies against the HIV-1 gp41 core structure. Microbiol Immunol 2006; 50:131-134.
28. Caffrey M, Kaufman J, Stahl S, Wingfield P, Gronenborn AM, Clore GM. Monomer-trimer equilibrium of the ectodomain of SIV gp41: insight into the mechanism of peptide inhibition of HIV infection. Protein Sci 1999; 8:1904-1907.
29. Sackett K, Wexler-Cohen Y, Shai Y. Characterization of the HIV N-terminal fusion peptide containing region in context of key gp41 fusion conformation. J Biol Chem 2006; 281:21755-21762.
30. Ryu J-R, Jin B-S, Suh M-J, Yoo Y-S, Yoon SH, Woo E-R, et al. Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity. Biochem Biophys Res Commun 1999; 265:625-629.
31. Trivedi VD, Cheng S-F, Wu C-W, Karthikeyan R, Chen C-J, Chang D-K. The LLSGIV strech of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20. Protein Eng 2003; 16:311-317.
32. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2:1075-1082.
33. Markosyan RM, Cohen FS, Melikyan GB. Time-resolved imaging of HIV-1 env-mediated lipid and content mixing between a single virion and cell membrane. Mol Biol Cell 2005; 16:5502-5513.
34. Finnegan CM, Berg W, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol 2002; 76:12123-12134.
35. Louis JM, Nesheiwat I, Chang L, Clore GM, Bewley CA. Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem 2003; 278:20278-20285.
36. Gustchina E, Louis JM, Lam SN, Bewley CA, Clore GM. A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol 2007; 81:12946-12953.